Summary
Danaher Corporation's Q2 2014 report indicates solid overall performance with a 5.0% increase in consolidated sales compared to the prior year period, driven by a 3.0% organic growth from existing businesses and 1.5% from acquisitions. High-growth markets, particularly in Asia, led the sales expansion, while developed markets showed more modest growth. The company continues to prioritize strategic acquisitions, having completed fourteen in the first half of 2014 for $607 million, complementing its Life Sciences & Diagnostics, Environmental, Dental, and Test & Measurement segments. Profitability remained strong with operating profit margins at 17.9% for the quarter, slightly up from 17.8% in the prior year. This was achieved despite dilutive effects from recent acquisitions, which were offset by cost savings from restructuring efforts and productivity improvements. The company is investing in new product development and sales initiatives, leading to a slight increase in R&D expenses as a percentage of sales. Danaher's liquidity position is robust, with $3.3 billion in cash and cash equivalents as of June 27, 2014, and substantial operating cash flow generation, enabling continued investment and debt management.
Financial Highlights
50 data points| Revenue | $4.78B |
| Cost of Revenue | $2.34B |
| Gross Profit | $2.49B |
| R&D Expenses | $336.40M |
| SG&A Expenses | $1.39B |
| Operating Income | $875.50M |
| Interest Expense | $33.20M |
| Net Income | $676.40M |
| EPS (Basic) | $0.96 |
| EPS (Diluted) | $0.95 |
| Shares Outstanding (Basic) | 701.20M |
| Shares Outstanding (Diluted) | 715.60M |
Key Highlights
- 1Consolidated sales increased by 5.0% year-over-year for the three and six months ended June 27, 2014, driven by 3.0% from existing businesses and 1.5% from acquisitions.
- 2High-growth markets showed strong performance, with sales from existing businesses in these regions growing at a high-single digit rate in Q2 2014.
- 3Danaher completed fourteen acquisitions in the first six months of 2014, totaling $607 million, primarily in Life Sciences & Diagnostics, Environmental, Dental, and Test & Measurement segments.
- 4Operating profit margins were maintained at 17.9% for Q2 2014, up from 17.8% in Q2 2013, with favorable impacts from higher sales volumes and cost savings, partially offset by acquisition dilution.
- 5The Test & Measurement segment experienced a 2.0% decline in sales from existing businesses due to softness in communications businesses, though other areas showed stability or growth.
- 6Life Sciences & Diagnostics segment demonstrated strong growth, with existing business sales up 5.0% in Q2 2014, driven by diagnostics and life sciences tools.
- 7The company maintains a strong liquidity position with $3.3 billion in cash and cash equivalents as of June 27, 2014, and generated $1.5 billion in operating cash flow for the first half of 2014.